Skip to content
Screener

BioCryst Pharmaceuticals BCRX Q3 2025 earnings

Reported November 3, 2025 · Before market open

Revenue$159.4MBeat by $8.1M
EPS$0.06Miss by $0.01
Revenue estimate$151.3M
EPS estimate$0.07

Next report

Nov 2, 2026 (in a month)
Revenue estimate$165.7M
EPS estimate$0.10

Financials

Q3 2025

Income statement

See full
Revenue$159.4M+36.1%
Gross profit$157.2M+38.1%
Operating income$29.6M+285%
Net income$12.9M+192%
EPS (diluted)$0.06+186%

Balance sheet

See full
Cash & equivalents$84.1M-13.2%
Total debt$207.8M-36.9%
Total equity-$387.9M+17.2%
Total assets$446.4M-9.1%

Cash flow

See full
Operating cash flow$41.6M—
CapEx$1.3M+2,178%
Free cash flow$40.3M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.59B+1.3%
Enterprise value$1.72B-4.9%
P/S2.7×-1.2×

Profitability

See full
Gross margin97.4%-0.7pp
Operating margin12.7%+8.8pp
Net margin-1.5%-0.7pp
FCF margin8%—

Returns & leverage

See full
Current ratio1.9×-0.9×

Segments

By segment

See full
Reportable Segment$159.4M+36.1%

FAQ

When did BioCryst Pharmaceuticals report Q3 2025 earnings?
BioCryst Pharmaceuticals (BCRX) reported Q3 2025 earnings on November 3, 2025 before market open.
What were BioCryst Pharmaceuticals's Q3 2025 revenue and EPS?
BioCryst Pharmaceuticals reported revenue of $159.4M and eps of $0.06 for Q3 2025.
Did BioCryst Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $151.3M by $8.1M. EPS missed the consensus estimate of $0.07 by $0.01.
How did BioCryst Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 36.1% from $117.1M a year earlier.
Where can I find BioCryst Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-006881) and the 10-Q periodic report (0001628280-25-048785) directly on SEC EDGAR. The filing index links above go to sec.gov.